Experimental Hematology & Oncology

Papers
(The median citation count of Experimental Hematology & Oncology is 5. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)
ArticleCitations
Construction and characterization of chimeric FcγR T cells for universal T cell therapy132
Telomeres, telomerase, and cancer: mechanisms, biomarkers, and therapeutics129
Suppression of CYLD by HER3 confers ovarian cancer platinum resistance via inhibiting apoptosis and by inducing drug efflux114
Cell membrane patches transfer CAR molecules from a cellular depot to conventional T cells for constructing innovative fused-CAR-T cells without necessitating genetic modification107
The roles of tissue resident macrophages in health and cancer95
ProNGF promotes brain metastasis through TrkA/EphA2 induced Src activation in triple negative breast cancer cells91
Allogeneic stem cell transplantation may overcome the adverse impact of myelofibrosis on the prognosis of myelodysplastic syndrome74
Comprehensive antitumor immune response boosted by dual inhibition of SUMOylation and MEK in MYC-expressing KRAS-mutant cancers70
Venetoclax-based therapy for relapsed or refractory acute myeloid leukemia: latest updates from the 2023 ASH annual meeting61
Metastatic clear-cell renal cell carcinoma: a frequent NOTCH1 mutation predictive of response to anti-NOTCH1 CB-103 treatment58
The multi-CDK inhibitor dinaciclib reverses bromo- and extra-terminal domain (BET) inhibitor resistance in acute myeloid leukemia via inhibition of Wnt/β-catenin signaling56
ASAP2 interrupts c-MET-CIN85 interaction to sustain HGF/c-MET-induced malignant potentials in hepatocellular carcinoma55
Age-related accumulation of B-1 cell progenitors in mice reflects changes in miR15a/16-1 expression and radioresistance capacity52
A new dosing regimen of ropeginterferon alfa-2b is highly effective and tolerable: findings from a phase 2 study in Chinese patients with polycythemia vera47
Sphingosine kinase 1 contributes to the metastatic potential of epithelial ovarian cancer to the adipocyte-rich niche47
Mutational signatures of synchronous and metachronous brain metastases from lung adenocarcinoma46
Spliceosome inhibitor induces human hematopoietic progenitor cell reprogramming toward stemness45
Next-generation sequencing for MRD monitoring in B-lineage malignancies: from bench to bedside45
DLC1 deficiency at diagnosis predicts poor prognosis in acute myeloid leukemia45
Ubiquitin-specific protease 28: the decipherment of its dual roles in cancer development45
CD44 promotes hepatocellular carcinoma progression via upregulation of YAP45
Molecular correlation of response to pyrotinib in advanced NSCLC with HER2 mutation: biomarker analysis from two phase II trials44
A bile-based microRNA signature for differentiating malignant from benign pancreaticobiliary disease42
Venetoclax-based therapy for relapsed or refractory acute myeloid leukemia: latest updates from the 2022 ASH annual meeting42
CRISPR/Cas9-mediated knockout of intracellular molecule SHP-1 enhances tumor-killing ability of CD133-targeted CAR T cells in vitro40
cGAS-ISG15-RAGE axis reprogram necroptotic microenvironment and promote lymphatic metastasis in head and neck cancer39
CUL4A-DDB1-circRFWD2 E3 ligase complex mediates the ubiquitination of p27 to promote multiple myeloma proliferation39
Combined inhibition of MET and VEGF enhances therapeutic efficacy of EGFR TKIs in EGFR-mutant non-small cell lung cancer with concomitant aberrant MET activation38
Identifying ADGRG1 as a specific marker for tumor-reactive T cells in acute myeloid leukemia37
Prospective pharmacotyping of urothelial carcinoma organoids for drug sensitivity prediction – feasibility and real world experience34
Correction: ScRNA-seq revealed an immunosuppression state and tumor microenvironment heterogeneity related to lymph node metastasis in prostate cancer33
Single-cell analysis defines highly specific leukemia-induced neutrophils and links MMP8 expression to recruitment of tumor associated neutrophils during FGFR1 driven leukemogenesis33
Targeting ST8SIA6-AS1 counteracts KRASG12C inhibitor resistance through abolishing the reciprocal activation of PLK1/c-Myc signaling33
Cytokine-based models for efficient differentiation between infection and cytokine release syndrome in patients with hematological malignancies33
Bispecific antibodies and dual-targeting CAR-T cells for multiple myeloma: latest updates from the 2023 ASCO annual meeting32
The role of pyroptosis and gasdermin family in tumor progression and immune microenvironment31
Efficacy and safety of immune checkpoint inhibitors in metastatic penile squamous cell carcinoma: a retrospective multicenter analysis30
Leukemia stem cell-bone marrow microenvironment interplay in acute myeloid leukemia development30
The emerging scenario of immunotherapy for T-cell Acute Lymphoblastic Leukemia: advances, challenges and future perspectives30
Current approaches to develop “off-the-shelf” chimeric antigen receptor (CAR)-T cells for cancer treatment: a systematic review29
Role of gut microbiome in cancer immunotherapy: from predictive biomarker to therapeutic target27
CircFBXW7 in patients with T-cell ALL: depletion sustains MYC and NOTCH activation and leukemia cell viability27
Targeting the integrated stress response in hematologic malignancies27
A novel and efficient CD22 CAR-T therapy induced a robust antitumor effect in relapsed/refractory leukemia patients when combined with CD19 CAR-T treatment as a sequential therapy27
Focal adhesion kinase: from biological functions to therapeutic strategies26
New insights into epigenetic regulation of resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms and therapeutic opportunities26
Role of the lectin pathway of complement in hematopoietic stem cell transplantation-associated endothelial injury and thrombotic microangiopathy26
TRIM family contribute to tumorigenesis, cancer development, and drug resistance26
Chimeric antigen receptor engineered natural killer cells for cancer therapy25
Fecal microbiota transplantation combined with ruxolitinib as a salvage treatment for intestinal steroid-refractory acute GVHD25
Surface TREM2 on circulating M-MDSCs as a novel prognostic factor for adults with treatment-naïve diffuse large B-cell lymphoma25
Targeting and cytotoxicity of chimeric antigen receptor T cells grafted with PD1 extramembrane domain24
ALKBH5 prevents hepatocellular carcinoma progression by post-transcriptional inhibition of PAQR4 in an m6A dependent manner24
Targeting hepcidin in colorectal cancer triggers a TNF-dependent-gasdermin E-driven immunogenic cell death response24
Ibrutinib and acalabrutinib use and risk of incident atrial fibrillation: a propensity-matched analysis23
A proinflammatory response and polarized differentiation of stromal elements characterizes the murine myeloma bone marrow niche23
Lactylation modification in cancer: mechanisms, functions, and therapeutic strategies23
CAR-T cell combination therapies in hematologic malignancies23
Correction: New insights into epigenetic regulation of resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms and therapeutic opportunities22
HIV associated lymphoma: latest updates from 2023 ASH annual meeting22
Correction: Breast cancer heterogeneity and its implication in personalized precision therapy22
A Fab of trastuzumab to treat HER2 overexpressing breast cancer brain metastases22
Small cell lung cancer: emerging subtypes, signaling pathways, and therapeutic vulnerabilities22
Enhanced cellular therapy: revolutionizing adoptive cellular therapy21
Recent updates on central nervous system prophylaxis in patients with high-risk diffuse large B-cell lymphoma21
All-in-one CRISPR/Cas-engineered glucocorticoid-receptor knock-out EBV-gp350-CAR knock-in T cells are potent and resistant to dexamethasone20
1q jumping translocation as a biomarker in myeloid malignancy: frequently mutated genes associated with bad prognosis and low survival20
Molecular profiling of biliary tract cancers reveals distinct genomic landscapes between circulating and tissue tumor DNA20
Function and clinical significance of N6-methyladenosine in digestive system tumours20
Transfer RNA-derived small RNA: an emerging small non-coding RNA with key roles in cancer20
Serologic response and safety of COVID-19 vaccination in HSCT or CAR T-cell recipients: a systematic review and meta-analysis20
Biomechanics in the tumor microenvironment: from biological functions to potential clinical applications19
GPR68-ATF4 signaling is a novel prosurvival pathway in glioblastoma activated by acidic extracellular microenvironment19
Correction: Unraveling the structures, functions and mechanisms of epithelial membrane protein family in human cancers19
COVID-19 vaccination associated severe immune thrombocytopenia19
MSCsDB: a database of single-cell transcriptomic profiles and in-depth comprehensive analyses of human mesenchymal stem cells18
Progression patterns in monoclonal gammopathy of undetermined significance and multiple myeloma outcome: a cohort study in 42 patients18
Genome-wide CRISPR/Cas9 library screening identified ATM signaling network genes as critical drivers for resistance to ATR inhibition in soft-tissue sarcomas: synthetic lethality and therapeutic impli18
Platelet-driven coagulopathy in COVID-19 patients: in comparison to seasonal influenza cases18
Comprehensive analysis of clinical, pathological, and genomic characteristics of follicular helper T-cell derived lymphomas18
Cell competition between wild-type and JAK2V617F mutant cells prevents disease relapse after stem cell transplantation in a murine model of myeloproliferative neoplasm17
Multi-omic profiling of the leukemic microenvironment shows bone marrow interstitial fluid is distinct from peripheral blood plasma17
RNA sequencing identifies novel regulated IRE1-dependent decay targets that affect multiple myeloma survival and proliferation17
Selinexor in combination with standard chemotherapy in patients with advanced or metastatic solid tumors17
HOXA13 promotes gastric cancer progression partially via the FN1-mediated FAK/Src axis17
CTP synthase 2 predicts inferior survival and mediates DNA damage response via interacting with BRCA1 in chronic lymphocytic leukemia16
Adefovir dipivoxil inhibits APL progression through degradation of the oncoprotein PML-RARA16
CircRIC8B regulates the lipid metabolism of chronic lymphocytic leukemia through miR199b-5p/LPL axis16
GPR109A controls neutrophil extracellular traps formation and improve early sepsis by regulating ROS/PAD4/Cit-H3 signal axis16
ANXA6/TRPV2 axis promotes lymphatic metastasis in head and neck squamous cell carcinoma by inducing autophagy15
Phase 2 trial of intravenous oncolytic virus JX-594 combined with low-dose cyclophosphamide in patients with advanced breast cancer15
Roles of N6-methyladenosine (m6A) modifications in gynecologic cancers: mechanisms and therapeutic targeting15
Molecular characterization of the CXCR4 / CXCR7 axis in germ cell tumors and its targetability using nanobody-drug-conjugates15
Alpha-B-Crystallin overexpression is sufficient to promote tumorigenesis and metastasis in mice15
LINP1 represses unfolded protein response by directly inhibiting eIF2α phosphorylation to promote cutaneous squamous cell carcinoma15
Combination of percutaneous thermal ablation and adoptive Th9 cell transfer therapy against non-small cell lung cancer14
The progress of novel strategies on immune-based therapy in relapsed or refractory diffuse large B-cell lymphoma14
Exploiting E3 ubiquitin ligases to reeducate the tumor microenvironment for cancer therapy14
Secretogranin II influences the assembly and function of MHC class I in melanoma14
NK cell transfer overcomes resistance to PD-(L)1 therapy in aged mice14
Decoding leukemia at the single-cell level: clonal architecture, classification, microenvironment, and drug resistance13
Analysis of CD20 and PD-L1 levels on small extracellular vesicles (sEV) produced by DLBCL cells and EBV-transformed B cells, and potential role in T cell inhibition13
Nuclear porcupine mediates XRCC6/Ku70 S-palmitoylation in the DNA damage response13
The HSP90-MYC-CDK9 network drives therapeutic resistance in mantle cell lymphoma13
Targeting natural killer cells: from basic biology to clinical application in hematologic malignancies13
Chimeric antigen receptor-T cell therapy for T cell-derived hematological malignancies13
Polyclonal evolution of Fanconi anemia to MDS and AML revealed at single cell resolution12
Chimeric antigen receptor T-cell therapy for relapsed and refractory thyroid cancer12
Decitabine in combination with fludarabine and cyclophosphamide as a lymphodepletion regimen followed by CD19/CD22 bispecific targeted CAR T-cell therapy significantly improves survival in relapsed/re12
Advances in adoptive cellular immunotherapy and therapeutic breakthroughs in multiple myeloma12
Regulatory T cells contribute to the immunosuppressive phenotype of neutrophils in a mouse model of chronic lymphocytic leukemia12
Successful administration of chimeric antigen receptor (CAR) T-cell therapy in patients requiring hemodialysis12
Chinese expert consensus on Bruton tyrosine kinase inhibitors in the treatment of B-cell malignancies12
Progress in understanding the mechanisms of resistance to BCL-2 inhibitors12
Correction to: Bispecific antibodies and dual-targeting CAR-T cells for multiple myeloma: latest updates from the 2023 ASCO annual meeting12
The current landscape of using direct inhibitors to target KRASG12C-mutated NSCLC12
Introducing AI to the molecular tumor board: one direction toward the establishment of precision medicine using large-scale cancer clinical and biological information11
METTL3 modulates m6A modification of CDC25B and promotes head and neck squamous cell carcinoma malignant progression11
Current insight into the regulation of PD-L1 in cancer11
Bridging therapy with histotripsy prior to liver transplantation for hepatocellular carcinoma: a first case report11
Chidamide and apatinib are therapeutically synergistic in acute myeloid leukemia stem and progenitor cells11
Highly immunosuppressive myeloid cells correlate with early relapse after allogeneic stem cell transplantation11
Emerging therapeutic frontiers in cancer: insights into posttranslational modifications of PD-1/PD-L1 and regulatory pathways11
Targeting PD-1/PD-L1 pathway in myelodysplastic syndromes and acute myeloid leukemia11
Myeloid-derived suppressor cells in hematologic malignancies: two sides of the same coin10
ScRNA-seq revealed an immunosuppression state and tumor microenvironment heterogeneity related to lymph node metastasis in prostate cancer10
Breast cancer heterogeneity and its implication in personalized precision therapy10
METTL1 mediated tRNA m7G modification promotes leukaemogenesis of AML via tRNA regulated translational control10
Ferroptosis: a novel regulated cell death participating in cellular stress response, radiotherapy, and immunotherapy10
Novel insights into TCR-T cell therapy in solid neoplasms: optimizing adoptive immunotherapy10
Bruton tyrosine kinase inhibitors in B-cell lymphoma: beyond the antitumour effect10
Role of m6A writers, erasers and readers in cancer10
Roles of the intestinal microbiota and microbial metabolites in acute GVHD10
High efficacy of huCD20-targeted AcTaferon in humanized patient derived xenograft models of aggressive B cell lymphoma10
Tumor battlefield within inflamed, excluded or desert immune phenotypes: the mechanisms and strategies10
Arsenic trioxide synergistically promotes the antileukaemic activity of venetoclax by downregulating Mcl-1 in acute myeloid leukaemia cells10
The gut microbiota as a booster for radiotherapy: novel insights into radio-protection and radiation injury10
Atezolizumab plus bevacizumab combination enables an unresectable hepatocellular carcinoma resectable and links immune exclusion and tumor dedifferentiation to acquired resistance9
Tanshinone IIA attenuates the stemness of breast cancer cells via targeting the miR-125b/STARD13 axis9
Challenges and strategies associated with CAR-T cell therapy in blood malignancies9
A non-conditioned bone marrow transplantation mouse model to study clonal hematopoiesis and myeloid malignancies9
Novel agents and clinical trials in castration-resistant prostate cancer: latest updates from 2023 ASCO-GU Cancers Symposium9
Generation and clinical potential of functional T lymphocytes from gene-edited pluripotent stem cells9
Follow our path with asparaginase activity: one technique, but different uses in clinical practice9
Low expression of PEBP1P2 promotes metastasis of clear cell renal cell carcinoma by post-transcriptional regulation of PEBP1 and KLF13 mRNA9
Radiation-induced exosomal miR-21 enhances tumor proliferation and invasiveness in breast cancer: implications for poor prognosis in radiotherapy patients9
Strain-dependent modifiers exacerbate familial leukemia caused by GATA1-deficiency8
Calcium oxalate crystals trigger epithelial-mesenchymal transition and carcinogenic features in renal cells: a crossroad between kidney stone disease and renal cancer8
The immunometabolic landscape of the bone marrow microenvironment in acute myeloid leukemia8
Targeting TIM-3 for hematological malignancy: latest updates from the 2022 ASH annual meeting8
Application patterns and outcomes of hematopoietic stem cell transplantation in peripheral T-cell lymphoma patients: a multicenter real-world study in China8
Disrupting Notch signaling related HES1 in myeloid cells reinvigorates antitumor T cell responses8
Three-dimensional chromatin landscapes in MLLr AML8
Vertical targeting of the PI3K/AKT pathway at multiple points is synergistic and effective for non-Hodgkin lymphoma8
A Pig-a conditional knock-out mice model mediated by Vav-iCre: stable GPI-deficient and mild hemolysis8
Depletion of polyfunctional CD26highCD8+ T cells repertoire in chronic lymphocytic leukemia8
Single-cell transcriptome analysis reveals stem cell-like subsets in the progression of Waldenström’s macroglobulinemia8
Novel agents and regimens in relapsed or refractory peripheral T-cell lymphoma: latest updates from 2023 ASH annual meeting8
Enhanced depletion of MLL-fusion proteins in acute leukemia: potential for improved therapeutic outcomes8
Elevated LDH greater than 400 U/L portends poorer overall survival in diffuse large B-cell lymphoma patients treated with CD19 CAR-T cell therapy in a real world multi-ethnic cohort8
DCF versus doublet chemotherapy as first-line treatment of advanced squamous anal cell carcinoma: a multicenter propensity score-matching study8
Correction to: Roles of tumor-associated macrophages in tumor progression: implications on therapeutic strategies8
The metabolic adaptation mechanism of metastatic organotropism8
Identification of potential resistance mechanisms and therapeutic targets for the relapse of BCMA CAR-T therapy in relapsed/refractory multiple myeloma through single-cell sequencing8
PD-L1+ macrophages are associated with favorable features in primary mediastinal (thymic) large B-cell lymphoma8
CD19/CD22 CAR-T-cell cocktail therapy following autologous transplantation is an optimizing strategy for treating relapsed/refractory central nervous system lymphoma8
CAR-macrophages targets CD26 to eliminate chronic myeloid leukemia stem cells8
Heat-killed Prevotella intermedia promotes the progression of oral squamous cell carcinoma by inhibiting the expression of tumor suppressors and affecting the tumor microenvironment8
Advances in nano-immunotherapy for hematological malignancies7
Learn from antibody–drug conjugates: consideration in the future construction of peptide-drug conjugates for cancer therapy7
Mesothelin-targeted CAR-T cells secreting NKG2D-BiTEs exhibit potent efficacy against triple-negative breast cancer7
Exosomal PD-L1 and lactate versus tissue PD-L1 as biomarkers for clinical outcomes of PD-1 Blockade plus chemotherapy in metastatic esophagogastric signet ring cell carcinoma7
Recent advances in Lynch syndrome7
Identification of a novel NPM1 mutation in acute myeloid leukemia7
TCR engineered T cells for solid tumor immunotherapy7
Post-translational modifications of immune checkpoints: unlocking new potentials in cancer immunotherapy7
Engineered circular RNA-based DLL3-targeted CAR-T therapy for small cell lung cancer7
Matching-adjusted indirect comparison of efficacy and safety of lisocabtagene maraleucel and mosunetuzumab for the treatment of third-line or later relapsed or refractory follicular lymphoma7
Modified dendritic cell-derived exosomes activate both NK cells and T cells through the NKG2D/NKG2D-L pathway to kill CML cells with or without T315I mutation7
Molecular profiling of skin cells identifies distinct cellular signatures in radiation-induced skin injury across various stages in the murine dataset7
Single VHH-directed BCMA CAR-NK cells for multiple myeloma6
IL-39 promotes chronic graft-versus-host disease by increasing T and B Cell pathogenicity6
MET amplification identified by next-generation sequencing and its clinical relevance for MET inhibitors6
TET2 downregulation enhances the antitumor efficacy of CD19 CAR T cells in a preclinical model6
Hetrombopag plus porcine ATG and cyclosporine for the treatment of aplastic anaemia: early outcomes of a prospective pilot study6
VISTA drives macrophages towards a pro-tumoral phenotype that promotes cancer cell phagocytosis yet down-regulates T cell responses6
Dlk1 maintains adult mice long-term HSCs by activating Notch signaling to restrict mitochondrial metabolism6
Inhibition of CDC20 potentiates anti-tumor immunity through facilitating GSDME-mediated pyroptosis in prostate cancer6
Current advances and challenges in CAR T-Cell therapy for solid tumors: tumor-associated antigens and the tumor microenvironment6
TLR7/8 signaling activation enhances the potency of human pluripotent stem cell-derived eosinophils in cancer immunotherapy for solid tumors6
Therapeutic synergy of Triptolide and MDM2 inhibitor against acute myeloid leukemia through modulation of p53-dependent and -independent pathways6
Profiling of somatic mutations and fusion genes in acute myeloid leukemia patients with FLT3-ITD or FLT3-TKD mutation at diagnosis reveals distinct evolutionary patterns6
The emerging roles of SUMOylation in the tumor microenvironment and therapeutic implications6
m6A binding protein YTHDF2 in cancer6
Alcohol accelerates the development of esophageal squamous cell carcinoma through elevated Gram-negative bacteria in peripheral circulation6
Hematopoietic stem/progenitor cell transplantation recovers immune defects and prevents lymphomas in Atm-deficient mice6
Understanding the versatile roles and applications of EpCAM in cancers: from bench to bedside6
The natural FGF-trap long pentraxin 3 inhibits lymphangiogenesis and lymphatic dissemination5
IRF4 expression is low in Philadelphia negative myeloproliferative neoplasms and is associated with a worse prognosis5
Identification of a novel subtype of SPP1 + macrophages expressing SIRPα: implications for tumor immune evasion and treatment response prediction5
Caspase-8 contributes to an immuno-hot microenvironment by promoting phagocytosis via an ecto-calreticulin-dependent mechanism5
JOSD2 regulates PKM2 nuclear translocation and reduces acute myeloid leukemia progression5
Neoantigen-specific TCR-T cell-based immunotherapy for acute myeloid leukemia5
Modelling acquired resistance to DOT1L inhibition exhibits the adaptive potential of KMT2A-rearranged acute lymphoblastic leukemia5
Therapeutic activation of G protein-coupled estrogen receptor 1 in Waldenström Macroglobulinemia5
Myelodysplastic syndromes are multiclonal diseases derived from hematopoietic stem and progenitor cells5
Metabolic cross-talk within the bone marrow milieu: focus on multiple myeloma5
Successful salvage therapy for refractory primary cutaneous gamma-delta T-cell lymphoma with a combination of brentuximab vedotin and gemcitabine5
A novel E-cadherin/SOX9 axis regulates cancer stem cells in multiple myeloma by activating Akt and MAPK pathways5
circRanGAP1/miR-27b-3p/NRAS Axis may promote the progression of hepatocellular Carcinoma5
The HSP90 inhibitor KW-2478 depletes the malignancy of BCR/ABL and overcomes the imatinib-resistance caused by BCR/ABL amplification5
IHCH9033, a novel class I HDAC inhibitor, synergizes with FLT3 inhibitor and rescues quizartinib resistance in FLT3-ITD AML via enhancing DNA damage response5
A multicenter phase II study of bendamustine, rituximab, and cytarabine (BRAC) for relapsed or refractory patients with follicular lymphoma or mantle cell lymphoma5
Hypoxia-associated circPRDM4 promotes immune escape via HIF-1α regulation of PD-L1 in hepatocellular carcinoma5
Novel cellular immunotherapies for hematological malignancies: recent updates from the 2021 ASH annual meeting5
CUL4B-DDB1-COP1-mediated UTX downregulation promotes colorectal cancer progression5
0.18764281272888